Ali Ozes
About Ali Ozes
Ali Ozes is the founder, CEO, and board member of a biotech company, known for developing a scalable method to identify novel small molecule binding domains and creating three first-in-class inhibitors targeting previously undruggable transcription factors.
Ali Ozes - Founder, CEO & Board Member
Ali Ozes serves as the Founder, CEO, and a Board Member. His leadership focuses on innovative drug discovery targeting disease-causing transcription factors (TFs). His strategic vision and management guide the company's efforts in developing first-in-class therapeutic inhibitors.
Ali Ozes' Scalable Method for Identifying Small Molecule Binding Domains
Ali Ozes has developed a scalable method for identifying novel small molecule binding domains. This proprietary method results in direct nanomolar (nM) binding to target transcription factors. The technique is particularly innovative as it focuses on the discovery of binding sites within intrinsically disordered domains, opening new possibilities for therapeutic interventions.
First-in-Class Inhibitors Developed by Ali Ozes
Ali Ozes has successfully developed three first-in-class inhibitors targeting previously undruggable transcription factors. These inhibitors are intended for treating conditions such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH), Ewing’s Sarcoma/Prostate Cancer, and Facioscapulohumeral muscular dystrophy (FSHD).
Ali Ozes' Platform for Small Molecule Discovery
The platform developed by Ali Ozes enables the discovery of small molecule binding sites within intrinsically disordered domains of transcription factors. This technology allows for the identification and subsequent targeting of previously elusive sites, aiming to drug disease-causing TFs and resulting in the creation of more specific and potentially safer therapies.